ArticleFrontiers in pharmacology2022
Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Metabolomic Insights into COVID-19 Severity: A Scoping Review.Metabolites · 2024Article
- Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis.Scientific reports · 2024Article
- Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches.Frontiers in immunology · 2024Review
- HDL-Related Parameters and COVID-19 Mortality: The Importance of HDL Function.Antioxidants (Basel, Switzerland) · 2023Article
- Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study.Pharmacological reports : PR · 2023Review
- Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches.Vaccines · 2023Review
- A comparative NMR-based metabolomics study of lung parenchyma of severe COVID-19 patients.Frontiers in molecular biosciences · 2023Article
- Untargeted analysis in post-COVID-19 patients reveals dysregulated lipid pathways two years after recovery.Frontiers in molecular biosciences · 2023Article
- Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Frontiers in molecular biosciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.